1887

Abstract

The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a surveillance study established in 2004 to monitor the activity of tigecycline, the first glycylcycline, and comparator agents [-lactams (including penicillins, cephalosporins and carbapenems), glycopeptides, tetracyclines, fluoroquinolones and oxazolidinones] against Gram-positive and Gram-negative pathogens worldwide. This report examines 1692 isolates of collected in the continental United States between January 2004 and September 2005. Meticillin-resistant (MRSA) accounted for 52.0 % of isolates. Prevalence of MRSA by state ranged from 12.5 % in New Hampshire to 100 % in Kentucky. All isolates were susceptible to tigecycline, linezolid and vancomycin. , tigecycline was potent against both meticillin-susceptible (MSSA) (MIC and MIC=0.12 μg ml) and MRSA (MIC=0.12 μg ml; MIC=0.25 μg ml). Only a single isolate was resistant to three or more antimicrobial classes. Ninety-six isolates (5.7 %) were susceptible to the complete antimicrobial panel.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46710-0
2007-09-01
2019-11-20
Loading full text...

Full text loading...

/deliver/fulltext/jmm/56/9/1189.html?itemId=/content/journal/jmm/10.1099/jmm.0.46710-0&mimeType=html&fmt=ahah

References

  1. Anderegg, T. R., Sader, H. S., Fritsche, T. R., Ross, J. E. & Jones, R. N. ( 2005; ). Trends in linezolid susceptibility patterns: report from the 2002–2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int J Antimicrob Agents 26, 13–21.[CrossRef]
    [Google Scholar]
  2. Babinchak, T., Ellis-Grosse, E., Dartois, N., Rose, G. M. & Loh, E. ( 2005; ). The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. The Tigecycline 301 and 306 Study Groups. Clin Infect Dis 41, S354–S367.[CrossRef]
    [Google Scholar]
  3. Bergeron, J., Ammirati, M., Danley, D., James, L., Norcia, M., Retsema, J., Strick, C. A., Su, W.-G., Sutcliffe, J. & Wondrack, L. ( 1996; ). Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 40, 2226–2228.
    [Google Scholar]
  4. Bouchillon, S. K., Hoban, D. J., Johnson, B. M., Johnson, J. L., Hsiung, A. & Dowzicky, M. J. ( 2005; ). In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (T.E.S.T. Program; 2004). Diagn Microbiol Infect Dis 52, 173–179.[CrossRef]
    [Google Scholar]
  5. Boyce, J. M. ( 2005; ). Meticillin-resistant Staphylococcus aureus: USA. Lancet Infect Dis 5, 653–654.[CrossRef]
    [Google Scholar]
  6. Bozdogan, B., Esel, D., Whitener, C., Browne, F. A. & Appelbaum, P. C. ( 2003; ). Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 52, 864–868.[CrossRef]
    [Google Scholar]
  7. Bradford, P. A., Weaver-Sands, D. T. & Petersen, P. J. ( 2005; ). In vitro activity of tigecycline against isolates from patients enrolled in Phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 41, S315–S332.[CrossRef]
    [Google Scholar]
  8. Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R. & other authors ( 2003; ). Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348, 1342–1347.[CrossRef]
    [Google Scholar]
  9. Chen, C.-J. & Huang, Y.-C. ( 2005; ). Community-acquired methicillin-resistant Staphylococcus aureus in Taiwan. J Microbiol Immunol Infect 38, 376–382.
    [Google Scholar]
  10. CLSI ( 2005; ). Performance standard for antimicrobial susceptibility testing, document M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute.
  11. Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W. & Carmeli, Y. ( 2003; ). Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36, 53–59.[CrossRef]
    [Google Scholar]
  12. Cunha, B. A. ( 2005; ). Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 11 (Suppl. 4), 33–42.
    [Google Scholar]
  13. Daum, R. S., Ito, T., Hiramatsu, K., Hussain, F., Mongkolrattanothai, K., Jamklang, M. & Boyle-Vavra, S. ( 2002; ). A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 186, 1344–1347.[CrossRef]
    [Google Scholar]
  14. Ellis-Grosse, E. J., Babinchak, T., Dartois, N., Rose, G. & Loh, E. ( 2005; ). The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase 3 comparison studies with vancomycin-aztreonam. The Tigecycline 300 and 305 cSSSI Study Groups. Clin Infect Dis 41, S341–S353.[CrossRef]
    [Google Scholar]
  15. Engemann, J. J., Carmeli, Y., Cosgrove, S. E., Fowler, V. G., Bronstein, M. Z., Trivette, S. L., Briggs, J. P., Sexton, D. J. & Kaye, K. S. ( 2003; ). Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 36, 592–598.[CrossRef]
    [Google Scholar]
  16. Fritsche, T. R. & Jones, R. N. ( 2004; ). Antimicrobial activity of tigecycline (GA-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections. Int J Antimicrob Agents 24, 567–571.[CrossRef]
    [Google Scholar]
  17. Fritsche, T. R., Kirby, J. T. & Jones, R. N. ( 2004; ). In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn Microbiol Infect Dis 49, 201–209.[CrossRef]
    [Google Scholar]
  18. Fritsche, T. R., Sader, H. S., Stilwell, M. G., Dowzicky, M. J. & Jones, R. N. ( 2005; ). Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000–2004). Diagn Microbiol Infect Dis 52, 195–201.[CrossRef]
    [Google Scholar]
  19. Gomes, A. R., Vinga, S., Zavolan, M. & de Lencastre, H. ( 2005; ). Analysis of the genetic variability of virulence-related loci in epidemic clones of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49, 366–379.[CrossRef]
    [Google Scholar]
  20. Graffunder, E. M. & Venezia, R. A. ( 2002; ). Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 49, 999–1005.[CrossRef]
    [Google Scholar]
  21. Haddadin, A. S., Fappiano, S. A. & Lipsett, P. A. ( 2002; ). Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J 78, 385–392.[CrossRef]
    [Google Scholar]
  22. Hoban, D. J., Bouchillon, S. K., Johnson, B. M., Johnson, J. L. & Dowzicky, M. J. ( 2005; ). In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (T.E.S.T. Program, 2004). Diagn Microbiol Infect Dis 52, 215–227.[CrossRef]
    [Google Scholar]
  23. Katayama, Y., Ito, T. & Hiramatsu, K. ( 2000; ). A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 44, 1549–1555.[CrossRef]
    [Google Scholar]
  24. Koeth, L. M. & Miller, L. A. ( 2005; ). Evolving concepts of pharmaceutical company-sponsored surveillance studies. Clin Infect Dis 41 (Suppl. 4), S279–S282.[CrossRef]
    [Google Scholar]
  25. McAleese, F., Petersen, P., Ruzin, A., Dunman, P. M., Murphy, E., Projan, S. J. & Bradford, P. A. ( 2005; ). A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 49, 1865–1871.[CrossRef]
    [Google Scholar]
  26. Moran, G. J., Amii, R. N., Abrahamian, F. M. & Talan, D. A. ( 2005; ). Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 11, 928–930.[CrossRef]
    [Google Scholar]
  27. National Nosocomial Infections Surveillance System ( 2004; ). National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32, 470–485.[CrossRef]
    [Google Scholar]
  28. NCCLS ( 2003; ). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, document M7-A6. Wayne, PA: National Committee for Clinical Laboratory Standards.
  29. Oliveira, D. C., Milheiriço, C. & de Lencastre, H. ( 2006; ). Redefining a structural variant of staphylococcal cassette chromosome mec, SCCmec type VI. Antimicrob Agents Chemother 50, 3457–3459.[CrossRef]
    [Google Scholar]
  30. Padmanabhan, R. A. & Fraser, T. G. ( 2005; ). The emergence of methicillin-resistant Staphylococcus aureus in the community. Cleve Clin J Med 72, 235–241.[CrossRef]
    [Google Scholar]
  31. Peeters, M. J. & Sarria, J. C. ( 2005; ). Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci 330, 102–104.[CrossRef]
    [Google Scholar]
  32. Salgado, C. D., Farr, B. M. & Calfee, D. P. ( 2003; ). Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 36, 131–139.[CrossRef]
    [Google Scholar]
  33. Stemper, M. E., Shukla, S. K. & Reed, K. D. ( 2004; ). Emergence and spread of community-associated methicillin-resistant Staphylococcus aureus in rural Wisconsin, 1989 to 1999. J Clin Microbiol 42, 5673–5680.[CrossRef]
    [Google Scholar]
  34. Stevenson, K. B., Searle, K., Stoddard, G. J. & Samore, M. H. ( 2005; ). Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in rural communities, western United States. Emerg Infect Dis 11, 895–903.[CrossRef]
    [Google Scholar]
  35. Weber, J. T. ( 2005; ). Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 41, S269–S272.[CrossRef]
    [Google Scholar]
  36. Wilson, P., Andrews, J. A., Charlesworth, R., Walesby, R., Singer, M., Farrell, D. J. & Robbins, M. ( 2003; ). Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 51, 186–188.[CrossRef]
    [Google Scholar]
  37. Wyeth Pharmaceuticals ( 2005; ). Tygacil product insert. Philadelphia: Wyeth Pharmaceuticals.
  38. Young, L. S., Perdreau-Remington, F. & Winston, L. G. ( 2004; ). Clinical, epidemiologic, and molecular evaluation of a clonal outbreak of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 38, 1075–1083.[CrossRef]
    [Google Scholar]
  39. Zinner, S. H. ( 2005; ). Overview of antibiotic use and resistance: setting the stage for tigecycline. Clin Infect Dis 41, S289–S292.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46710-0
Loading
/content/journal/jmm/10.1099/jmm.0.46710-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error